Abstract
According to recent experience there is an unexpected high prevalence of treatment resistance in hypertension, i.e. an inefficiency of even complex treatment modalities, increasing the need for multi-drug regimens. Mostly, this applies to systolic hypertension which over the years was found to cause at least as much target organ damage as diastolic. In view of the high prevalence of hypertension, such resistance may be a rising concern. This might not only be due to inefficiency of drugs, but also to low blood pressure levels as treatment goals and to increasing patient age with more systolic hypertension. Over the past few years, some new evidence has accumulated that will contribute to a break-down of the complex of treatment resistance into several categories of both primary and secondary hypertension, the most important may be the high frequency of white-coat hypertension, aldosteronism, low-renin hypertension and adiposity. In turn, the new evidence may lead to effective treatment for nearly every patient suffering therapy resistance. Such efficiency is all the more wanted since blood pressures in these patients are often severe and fraught with serious complications.
Keywords: Aldosteronism, amiloride, guidelines, low-renin, randomized, refractory, trials
Current Drug Therapy
Title: An Increasing Incidence of Treatment Resistance in Hypertension?
Volume: 1 Issue: 3
Author(s): Ivar K. Eide
Affiliation:
Keywords: Aldosteronism, amiloride, guidelines, low-renin, randomized, refractory, trials
Abstract: According to recent experience there is an unexpected high prevalence of treatment resistance in hypertension, i.e. an inefficiency of even complex treatment modalities, increasing the need for multi-drug regimens. Mostly, this applies to systolic hypertension which over the years was found to cause at least as much target organ damage as diastolic. In view of the high prevalence of hypertension, such resistance may be a rising concern. This might not only be due to inefficiency of drugs, but also to low blood pressure levels as treatment goals and to increasing patient age with more systolic hypertension. Over the past few years, some new evidence has accumulated that will contribute to a break-down of the complex of treatment resistance into several categories of both primary and secondary hypertension, the most important may be the high frequency of white-coat hypertension, aldosteronism, low-renin hypertension and adiposity. In turn, the new evidence may lead to effective treatment for nearly every patient suffering therapy resistance. Such efficiency is all the more wanted since blood pressures in these patients are often severe and fraught with serious complications.
Export Options
About this article
Cite this article as:
Eide K. Ivar, An Increasing Incidence of Treatment Resistance in Hypertension?, Current Drug Therapy 2006; 1 (3) . https://dx.doi.org/10.2174/157488506778194893
DOI https://dx.doi.org/10.2174/157488506778194893 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
“Cardiovascular” Drugs in Rheumatoid Arthritis: Killing Two Birds with One Stone?
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Induction of Myocardial Fibrosis and Hypertrophy by Natriuretic Peptides
Vascular Disease Prevention (Discontinued) Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design Anti-Inflammatory Actions of the Heme Oxygenase-1 Pathway
Current Pharmaceutical Design Is there a Teratogenicity Risk Associated with Cannabis and Synthetic Cannabimimetics’ (‘Spice’) Intake?
CNS & Neurological Disorders - Drug Targets The Position of Endoscopic Procedures in the Treatment of Obesity
Current Clinical Pharmacology Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine The Role of Orexin System in Antipsychotics Induced Weight Gain
Current Psychiatry Reviews Renal Innervation in Resistant Hypertension: A Review of Pathophysiology and Renal Denervation as Potential Treatment
Current Hypertension Reviews Targeting Soluble Epoxide Hydrolase for Inflammation and Pain - An Overview of Pharmacology and the Inhibitors
Inflammation & Allergy - Drug Targets (Discontinued) Inhalation Delivery of Protein Therapeutics
Inflammation & Allergy - Drug Targets (Discontinued) Kounis Syndrome Following Beta-Lactam Antibiotic Use: Review of Literature
Inflammation & Allergy - Drug Targets (Discontinued) Gender, Hormones and the Transmissible Encephalopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Irreversible Inhibition of Serine Proteases – Design and In Vivo Activity of Diaryl α-Aminophosphonate Derivatives
Current Medicinal Chemistry Review of Clinic Trials: Agents Targeting c-Met
Reviews on Recent Clinical Trials Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease
Current Drug Metabolism ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology Preventive and Therapeutic Role of Muscle Contraction Against Chronic Diseases
Current Pharmaceutical Design Safety Analysis and Improved Cardiac Function Following Local Autologous Transplantation of CD133+ Enriched Bone Marrow Cells After Myocardial Infarction
Current Neurovascular Research Exercise in Youth with Type 1 Diabetes
Current Pediatric Reviews